Compass Therapeutics, Inc.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology. Its lead candidate, tovecimig, is a bispecific antibody targeting DLL4 and VEGF-A, which are involved in angiogenesis and tumor vascularization. The company also has CTX-471, an IgG4 monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Additionally, its pipeline includes CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1, and CTX-10726, a bispecific antibody targeting PD-1 and VEGF-A. These therapies are designed to treat various human diseases, primarily cancers.

Compass Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CMPX. Its shares are traded in U.S. dollars (USD). The company is headquartered in Boston, Massachusetts, and operates primarily in the United States.

Compass Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing antibody-based therapies for oncology. Biotechnology companies like Compass use biological processes and living organisms to create treatments, often targeting specific molecular pathways involved in diseases such as cancer.

Compass Therapeutics is headquartered in Boston, Massachusetts, United States. The company primarily serves the U.S. market, as indicated by its regional classification as 'us'. Its research and development activities are centered in the United States, and it focuses on developing therapies for patients with various human diseases, particularly cancers.

Compass Therapeutics' pipeline includes several antibody-based therapeutics. The lead candidate is tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, which are key to angiogenesis and tumor vascularization. Another candidate is CTX-471, an IgG4 monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. The company also has CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1 checkpoint inhibitors, and CTX-10726, a bispecific antibody targeting PD-1 and VEGF-A. These candidates are in clinical-stage development for oncology indications.